Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00939523 · OUTCOME

% Change in Prolactin From Baseline to Study End

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy · Source last updated 2020-01-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
percent change in prolactin
Interval / dispersion
Full Range
Time frame
Baseline and at 6 months

What was measured

Percent prolactin change from start of lapatinib to end of study participant participation

Analysis population: Prolactin results only reported on the 6 prolactinomas in the trial and not for the nonfunctioning tumors.

Groups in this outcome

Lapatinib

All participants will be asked to take Lapatinib 1250 mg po daily for a total of six months during the research study. Lapatinib: All participants will be asked to take Lapatinib daily for six months during the research study.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Lapatinib6

Reported measurements

Source class 1
Values in percent change in prolactin · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Lapatinib-7.0Not reported-78.5103.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -78.5
        upper Limit
        103.0
        value
        -7.0
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    units
    Participants
description
Percent prolactin change from start of lapatinib to end of study participant participation
dispersion Type
Full Range
groups
  1. description
    All participants will be asked to take Lapatinib 1250 mg po daily for a total of six months during the research study. Lapatinib: All participants will be asked to take Lapatinib daily for six months during the research study.
    id
    OG000
    title
    Lapatinib
param Type
MEDIAN
population Description
Prolactin results only reported on the 6 prolactinomas in the trial and not for the nonfunctioning tumors.
reporting Status
POSTED
time Frame
Baseline and at 6 months
title
% Change in Prolactin From Baseline to Study End
type
SECONDARY
unit Of Measure
percent change in prolactin

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice